Versartis, Inc. (NASDAQ:VSAR) SVP Paul Westberg sold 711 shares of Versartis stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $16.05, for a total transaction of $11,411.55. Following the sale, the senior vice president now owns 67,517 shares in the company, valued at $1,083,647.85. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Paul Westberg also recently made the following trade(s):

  • On Wednesday, April 19th, Paul Westberg sold 1,316 shares of Versartis stock. The stock was sold at an average price of $19.85, for a total transaction of $26,122.60.

Shares of Versartis, Inc. (VSAR) traded up 1.23% on Wednesday, hitting $16.50. 185,979 shares of the stock were exchanged. The company has a 50 day moving average of $17.02 and a 200 day moving average of $17.08. Versartis, Inc. has a 52-week low of $9.05 and a 52-week high of $24.00. The company’s market cap is $580.93 million.

Versartis (NASDAQ:VSAR) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by $0.14. Equities research analysts forecast that Versartis, Inc. will post ($2.94) earnings per share for the current year.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Versartis, Inc. (VSAR) SVP Sells 711 Shares of Stock” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/06/14/insider-selling-versartis-inc-vsar-svp-sells-711-shares-of-stock.html.

A number of research analysts have recently issued reports on VSAR shares. Canaccord Genuity restated a “buy” rating and issued a $28.00 price target on shares of Versartis in a research report on Wednesday, February 22nd. Barclays PLC started coverage on shares of Versartis in a research report on Thursday, March 9th. They issued an “overweight” rating and a $28.00 price target on the stock. Piper Jaffray Companies boosted their price target on shares of Versartis from $22.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 4th. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. Finally, Cantor Fitzgerald started coverage on shares of Versartis in a research report on Thursday, May 4th. They issued an “overweight” rating and a $34.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $25.13.

Several large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its stake in Versartis by 6.1% in the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock worth $94,096,000 after buying an additional 253,632 shares in the last quarter. FMR LLC increased its stake in Versartis by 0.9% in the fourth quarter. FMR LLC now owns 4,128,376 shares of the biopharmaceutical company’s stock worth $61,513,000 after buying an additional 37,745 shares in the last quarter. New Leaf Venture Partners L.L.C. purchased a new stake in Versartis during the fourth quarter worth about $30,384,000. Vanguard Group Inc. increased its stake in Versartis by 11.3% in the first quarter. Vanguard Group Inc. now owns 1,002,507 shares of the biopharmaceutical company’s stock worth $21,404,000 after buying an additional 101,578 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. increased its stake in Versartis by 6.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 511,610 shares of the biopharmaceutical company’s stock worth $7,623,000 after buying an additional 30,554 shares in the last quarter. Institutional investors and hedge funds own 78.14% of the company’s stock.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.